Hendra Gunosewoyo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9046874/publications.pdf

Version: 2024-02-01

44 papers	1,180 citations	394421 19 h-index	377865 34 g-index
44 all docs	44 docs citations	44 times ranked	1900 citing authors

#	Article	IF	Citations
1	Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis. Bioorganic Chemistry, 2021, 106, 104486.	4.1	12
2	Synthesis and Pharmacological Evaluation of Ïƒ2 Receptor Ligands Based on a 3â€Alkoxyisoxazole Scaffold: Potential Antitumor Effects against Osteosarcoma. ChemMedChem, 2021, 16, 524-536.	3.2	4
3	Imaging Cannabinoid Receptors: A Brief Collection of Covalent and Fluorescent Probes for CB. Australian Journal of Chemistry, 2021, 74, 416-432.	0.9	7
4	Synthesis and antitumour evaluation of indole-2-carboxamides against paediatric brain cancer cells. RSC Medicinal Chemistry, 2021, 12, 1910-1925.	3.9	1
5	Design, synthesis and evaluation of novel indole-2-carboxamides for growth inhibition of Mycobacterium tuberculosis and paediatric brain tumour cells. RSC Advances, 2021, 11, 15497-15511.	3.6	11
6	Sigma-1 Receptor Agonist TS-157 Improves Motor Functional Recovery by Promoting Neurite Outgrowth and pERK in Rats with Focal Cerebral Ischemia. Molecules, 2021, 26, 1212.	3.8	4
7	Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules. European Journal of Medicinal Chemistry, 2021, 213, 113202.	5.5	15
8	Facile synthesis and antimycobacterial activity of isoniazid, pyrazinamide and ciprofloxacin derivatives. Chemical Biology and Drug Design, 2021, 97, 1137-1150.	3.2	9
9	Therapeutic Potential of Coumestan Pks13 Inhibitors for Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	12
10	Synthesis and evaluation of tetrahydroisoquinoline derivatives against Trypanosoma brucei rhodesiense. European Journal of Medicinal Chemistry, 2021, 226, 113861.	5.5	2
11	Design, synthesis, and biological evaluation of novel arylcarboxamide derivatives as anti-tubercular agents. RSC Advances, 2020, 10, 7523-7540.	3.6	24
12	Synthesis and evaluation of various heteroaromatic benzamides as analogues of â€“ylidene-benzamide cannabinoid type 2 receptor agonists. Tetrahedron Letters, 2019, 60, 151019.	1.4	7
13	Revisiting the Î²-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	4
14	Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer. International Journal of Molecular Sciences, 2019, 20, 2112.	4.1	33
15	Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II. Journal of Medicinal Chemistry, 2019, 62, 3575-3589.	6.4	26
16	Therapeutic Inducers of Apoptosis in Ovarian Cancer. Cancers, 2019, 11, 1786.	3.7	44
17	Introducing nitrogen atoms to amidoalkylindoles: potent and selective cannabinoid type 2 receptor agonists with improved aqueous solubility. MedChemComm, 2019, 10, 2131-2139.	3.4	9
18	Kinase Targets for Mycolic Acid Biosynthesis in Mycobacterium tuberculosis. Current Molecular Pharmacology, 2019, 12, 27-49.	1.5	15

#	Article	IF	Citations
19	Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Journal of Medicinal Chemistry, 2018, 61, 791-803.	6.4	56
20	Novel spirocyclic tranylcypromine derivatives as lysine-specific demethylase 1 (LSD1) inhibitors. RSC Advances, 2018, 8, 1666-1676.	3.6	9
21	Efflux transporters and tight junction expression changes in human gastrointestinal cell lines cultured in defined medium vs serum supplemented medium. Life Sciences, 2018, 207, 138-144.	4.3	2
22	Kinase targets in CNS drug discovery. Future Medicinal Chemistry, 2017, 9, 303-314.	2.3	24
23	Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors. European Journal of Medicinal Chemistry, 2017, 141, 101-112.	5.5	27
24	Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor Agonists with in Vivo Efficacy in a Mouse Model of Multiple Sclerosis. Journal of Medicinal Chemistry, 2017, 60, 7067-7083.	6.4	29
25	Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models. Translational Oncology, 2017, 10, 669-678.	3.7	32
26	Development of Antidepressant Drugs Through Targeting Î±4Î²2-Nicotinic Acetylcholine Receptors. Neuromethods, 2016, , 207-225.	0.3	0
27	Synthesis and biological evaluation of novel hybrids of highly potent and selective Î±4Î²2-Nicotinic acetylcholine receptor (nAChR) partial agonists. European Journal of Medicinal Chemistry, 2016, 124, 689-697.	5.5	14
28	Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy. Journal of Medicinal Chemistry, 2016, 59, 6329-6343.	6.4	20
29	Stereoselective synthesis towards unnatural proline based amino acids. Arkivoc, 2016, 2016, 134-144.	0.5	5
30	Optimization of 2-Phenylcyclopropylmethylamines as Selective Serotonin 2C Receptor Agonists and Their Evaluation as Potential Antipsychotic Agents. Journal of Medicinal Chemistry, 2015, 58, 1992-2002.	6.4	31
31	Targeting the Number Two Infectious Disease Killer--Tuberculosis. Medicinal Chemistry Reviews, 2015, , 283-296.	0.1	1
32	The First CNS-Active Carborane: A Novel P2X₇ Receptor Antagonist with Antidepressant Activity. ACS Chemical Neuroscience, 2014, 5, 335-339.	3.5	118
33	Inhibition of GSK-3 Induces Differentiation and Impaired Glucose Metabolism in Renal Cancer. Molecular Cancer Therapeutics, 2014, 13, 285-296.	4.1	56
34	Indoleamides are active against drug-resistant Mycobacterium tuberculosis. Nature Communications, 2013, 4, 2907.	12.8	130
35	Structural analogs of huperzine A improve survival in guinea pigs exposed to soman. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1544-1547.	2.2	9
36	Preliminary Structureâ€“Activity Relationships and Biological Evaluation of Novel Antitubercular Indolecarboxamide Derivatives Against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains. Journal of Medicinal Chemistry, 2013, 56, 4093-4103.	6.4	118

#	Article	IF	Citations
37	Characterization of Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as Stimulators of Steroidogenesis. Journal of Medicinal Chemistry, 2013, 56, 5115-5129.	6.4	36
38	From Î±4Î²2 Nicotinic Ligands to the Discovery of Ïƒ1 Receptor Ligands: Pharmacophore Analysis and Rational Design. ACS Medicinal Chemistry Letters, 2012, 3, 1054-1058.	2.8	11
39	Identification of a Glycogen Synthase Kinaseâ€3Î² Inhibitor that Attenuates Hyperactivity in CLOCK Mutant Mice. ChemMedChem, 2011, 6, 1593-1602.	3.2	36
40	Structureâ€Guided Design of a Highly Selective Glycogen Synthase Kinaseâ€3Î² Inhibitor: a Superior Neuroprotective Pyrazolone Showing Antimania Effects. ChemMedChem, 2011, 6, 1587-1592.	3.2	14
41	P2X purinergic receptor ligands: recently patented compounds. Expert Opinion on Therapeutic Patents, 2010, 20, 625-646.	5.0	77
42	Purinergic P2X7 receptor antagonists: Chemistry and fundamentals of biological screening. Bioorganic and Medicinal Chemistry, 2009, 17, 4861-4865.	3.0	10
43	Cubyl amides: Novel P2X7 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3720-3723.	2.2	34
44	Molecular Probes for P2X7 Receptor Studies. Current Medicinal Chemistry, 2007, 14, 1505-1523.	2.4	42